Wellness Oncology & Hematology Wellness Oncology & Hematology's Location Contact Wellness Oncology & Hematology
Comprehensive Cancer & Hematology Treatment Center
Appointments: (818) 346-1773



West Hills Oncology & Hematology Center
WELLNESS ONCOLOGY & HEMATOLOGY
Offices in West Hills & Tarzana
Patient Portal  |  Contact Us



Comprehensive Cancer & Hematology Treatment Center
personalized care at your doorstep


< Back to all blogs

Some of our clinical trial patients get some good news!

By: Dr. Christopher Ho on April 21, 2014, 3:29 pm

As medical oncologists in Woodland Hills and Encino, we are proud to offer our patients the cutting edge in clinical trials and the opportunity to be involved in the latest medications. We also understand the anxiety that can come by being a patient in a clinical trial wherein the possibility of improvement is not guaranteed.

That said, clinical trials still remain one of the best ways the cancer community can forge ahead  with new therapy. Each medication now considered standard therapy at one point was "experimental" and builds upon the experience on prior therapies. Modern day clinical trials are national, even international and therefore have the benefit of the shared experience of many patients throughout the country, if not the world. 

Among our other clinical trials, we are proud to offer our patients a clinical trial in which a new medication Palbociclib is in combination with faslodex in hormone positive, Her 2 Negative metastatic breast cancer patients who have previously progressed on endocrine therapy.  Palbociclib is a CDK4/6-checkpoint inhibitor, which hampers a cancer cell's proliferation and cellular DNA synthesis by preventing cell-cycle progression, 

You can imagine our excitement when recently the final results of a randomized phase II study presented at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego was presented. In First-line treatment with the combination of palbociclib plus letrozole extended progression-free survival by approximately 50% in patients with metastatic estrogen receptor–positive, HER2-negative breast cancer.

You can read more details in the links below. Very encouraging news for our patients on clinical trial who have made that step of faith. 

http://www.nytimes.com/2014/04/07/business/breast-cancer-drug-shows-groundbreaking-results.html?hp&_r=0

http://www.ascopost.com/ViewNews.aspx?nid=15096

We have other clinical trials available including "triple-negative" breast cancer, lymphoma, and myelofibrosis. Please call us if interested.